Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Sep;30(5):e24.
doi: 10.1136/ejhpharm-2021-002819. Epub 2022 Mar 1.

Pancytopenia in a patient treated with fusidic acid and niraparib: a case report

Margaux Damerval  1 , Fernando Bazan  2 , Selim Omrani  3 , Marion Hugues  3 , Marie-Françoise Roux  3 , Joséphine Mayer  3
Affiliations
Case Reports

Pancytopenia in a patient treated with fusidic acid and niraparib: a case report

Margaux Damerval et al. Eur J Hosp Pharm. 2023 Sep.

Abstract

Fusidic acid is an antibiotic used in the treatment of staphylococcal infections. Niraparib is an anticancer drug indicated for the treatment of advanced ovarian cancer. The interaction between these two drugs has not been studied and is not referenced in drug databases. We present the case of a patient with pancytopenia who had been treated with fusidic acid and niraparib. No other treatment was taken by this patient. According to the literature, both substances can cause haematological toxicity. It seems unlikely that this is due to niraparib alone because it had been well tolerated by the patient for over a year before the pancytopenia was diagnosed. It was also perfectly well tolerated when it was reintroduced. We cannot determine whether this pancytopenia is due to fusidic acid alone or to a drug interaction between the two treatments. We therefore recommend caution in patients treated with this combination.

Keywords: breast neoplasms; case reports; drug incompatibility; medical oncology; pharmacy service, hospital.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Evolution of blood count.
Figure 2
Figure 2
Treatment plan.
See this image and copyright information in PMC

References

    1. Kraus CN, Burnstead BW. The safety record of fusidic acid in non-US markets: a focus on skin infections. Clin Infect Dis 2011;52 Suppl 7:S527–37. 10.1093/cid/cir168 - DOI - PubMed
    1. Résumé des caractéristiques du produit - Acide fusidique. Available: http://agence-prd.ansm.sante.fr/php/ecodex/rcp/R0207358.htm
    1. Résumé des caractéristiques du produit - Niraparib. Available: https://ec.europa.eu/health/documents/community-register/2017/2017111613...
    1. Moore KN, Mirza MR, Matulonis UA. The poly (ADP ribose) polymerase inhibitor niraparib: management of toxicities. Gynecol Oncol 2018;149:214–20. 10.1016/j.ygyno.2018.01.011 - DOI - PubMed
    1. Mirza MR, Monk BJ, Herrstedt J, et al. . Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 2016;375:2154–64. 10.1056/NEJMoa1611310 - DOI - PubMed

Publication types

MeSH terms